2. Gene
  3. Akt3 - thymoma viral proto-oncogene 3 Gene

Akt3 - thymoma viral proto-oncogene 3 Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Mus musculus

Also known as Nmf350; D930002M15Rik

Gene ID: 23797 | Gene type: protein coding

About Akt3

Chromosome 1: 176,847,639-177,085,769 reverse strand.GRCm39:CM000994.3

This gene has 4 transcripts (splice variants), 203 orthologues, 5 paralogues and is associated with 19 phenotypes. Broad expression in CNS E18 (RPKM 12.2), CNS E14 (RPKM 1.5) and 22 other tissues.

Summary

Predicted to enable ATP binding activity; protein kinase C binding activity; and protein serine/threonine kinase activity. Involved in positive regulation of angiogenesis and positive regulation of artery morphogenesis. Acts upstream of or within several processes, including brain morphogenesis; positive regulation of TOR signaling; and positive regulation of cell size. Predicted to be located in plasma membrane. Is expressed in several structures, including genitourinary system; musculature; nervous system; retina; and skin. Human ortholog(s) of this gene implicated in colon cancer; glioblastoma; prostate adenocarcinoma; prostate cancer; and renal cell carcinoma. Orthologous to human Akt3 (Akt serine/threonine kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Akt3 Products(1)

mRNA Protein Name
NM_011785.4 NP_035915.3 RAC-gamma serine/threonine-protein kinase

Akt3 Protein Structure

PH_PKB

PH_PKB: cd01241 (3 - 109)

STKc_PKB_gamma

STKc_PKB_gamma: cd05593 (131 - 478)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 479 a.a.
Protein Preferred Names Protein Names

RAC-gamma serine/threonine-protein kinase

PKB gamma

RAC-PK-gamma

protein kinase Akt-3

protein kinase B gamma

Recombinant Akt3 Proteins

Cat. No. Product Name Accession Purity
HY-P72817 AKT3 Protein, Mouse (sf9) Q9WUA6-1 (A106-E479) ≥95%

Related Agents

Clinical Phase
Bioactive Molecules (18)
Cat. No. Product Name Effect
Purity Phase
HY-15186 Ipatasertib Inhibitor 99.88% Phase 4
HY-15186A Ipatasertib dihydrochloride Inhibitor 99.27% Phase 4
HY-15431 Capivasertib Inhibitor 99.95% Phase 3
HY-10358 MK-2206 dihydrochloride Inhibitor 99.99% Phase 2
HY-19719 Miransertib Inhibitor 99.32% Phase 2
HY-15727 Afuresertib Inhibitor 99.53% Phase 2
HY-15965 Uprosertib Inhibitor 99.74% Phase 2
HY-19934A Pifusertib hydrochloride Inhibitor 96.71% Phase 2
HY-15727A Afuresertib hydrochloride Inhibitor 99.95% Phase 2
HY-19719A Miransertib hydrochloride Inhibitor 99.74% Phase 2
HY-108232 MK-2206 Inhibitor / Phase 2
HY-19934 Pifusertib Inhibitor / Phase 2
HY-15965A Uprosertib hydrochloride Inhibitor / Phase 2
HY-10249 GSK-690693 Inhibitor 98.46% Phase 1
HY-100018 BAY1125976 Inhibitor 99.52% Phase 1
HY-16071 AT13148 Inhibitor 99.21% Phase 1
HY-100501 M2698 Inhibitor 99.87% Phase 1
HY-137458 Vevorisertib Inhibitor / Phase 1
Pre-clinical Phase
Bioactive Molecules (20)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-10355 AKT inhibitor VIII Inhibitor 98.97% Unkown
HY-10425 A-443654 Inhibitor 98.50% Unkown
HY-137458A Vevorisertib trihydrochloride Inhibitor 99.13% Unkown
HY-12059 AT7867 Inhibitor 99.88% Unkown
HY-133120 INY-03-041 Inhibitor 99.74% Unkown
HY-151504 ALM301 Inhibitor 99.33% Unkown
HY-145282 MS170 Inhibitor 99.72% Unkown
HY-12059A AT7867 dihydrochloride Inhibitor 99.75% Unkown
HY-19982 AKT-IN-6 Inhibitor 99.08% Unkown
HY-126257 AKT-IN-3 Inhibitor 99.29% Unkown
HY-133120A INY-03-041 trihydrochloride Inhibitor 99.27% Unkown
HY-151613 MS15 Inhibitor / Unkown
HY-132302 Hu7691 Inhibitor / Unkown
HY-145281 MS98 Inhibitor / Unkown
HY-132302A Hu7691 free base Inhibitor / Unkown
HY-10357 MK-2206 free base Inhibitor / Unkown
HY-129119 Akt1/Akt2-IN-2 Inhibitor 98.57% Unkown
HY-147937 AKT-IN-13 Inhibitor / Unkown
HY-143611 AKT-IN-8 Inhibitor / Unkown
HY-16032 Akt1-IN-2 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Akt3 NCBI NCBI:10000